Shipment of GMP DMT, In Vitro HERG and Genotox Assays Completed, and In Vivo Toxicity Assays Underway Vancouver, British Columbia–(Newsfile Corp. – November 24, 2021) – Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“ Entheon” or the “Company“), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to provide an update on its upcoming…


Previous articlePsychedelic and Mysticism: The Debate Continues
Next articleSeelos Therapeutics Raises $20 Million in Private Placement of Senior Secured Convertible Note